NanoGroup is an innovative biotechnology company that combines groundbreaking innovations in nanotechnology with unique risk management capabilities.

NanoGroup S.A. focuses on the development of new medical technologies based on scientific research and development work in the field of nanoparticles.

The company’s mission is to enhance the effectiveness and safety of both existing and new therapies, as well as to develop innovative solutions aimed at saving human health and lives.

  • We are a complete research and development organization, created at the intersection of science, medicine, and business.
  • We focus on research areas with the potential for breakthrough changes.
  • We commercialize projects at an early stage of development.
  • Our technology is unique and protected by patents worldwide.

History

NanoGroup was founded as a result of groundbreaking discoveries made by a team of scientists from the Warsaw University of Technology in the field of nanoparticles. The high market potential and obvious future benefits allowed the company to secure funding from leading local Venture Capital funds. As part of its project diversification strategy, NanoGroup merged three companies representing three distinct technological lines. Since 2017, NanoGroup has been listed on the Warsaw Stock Exchange.

The initial stages of research were conducted in the company’s laboratory in Warsaw. As the research progressed and preclinical trials began, NanoGroup collaborated with leading research institutes from the United States, China, and Italy.
In addition to its main research stream, NanoGroup successfully completed two projects as a CRO, one of which was widely commercialized.

Subsidiaries

nanoSanguis

Respiratory gas transport systems: Blood substitute and the NanoOX system.

nanoVelos

Polysaccharide Nanocapsules for Targeted Therapy

nanoTHEAradiopharmaceuticals

Radioisotopes for diagnostics and treatment

Business Model

  • NanoGroup is an organization focused on the rapid commercialization of research results through partnerships with international biotechnology and pharmaceutical companies.
  • Depending on the project, the anticipated stage of partnership is the end of preclinical research or the first phase of clinical trials.
  • Projects are selected in such a way that their outcome is a significant innovation in a clearly defined segment – Global unmet health needs are preferred where the product provides clear value to patients.
  • Each project is part of a long-term risk management plan and the creation of lasting value for shareholders.

Estimated market size for our projects:

$billion

System NanOX

$million

NanoVelos Platform (per project)

$billion

Blood Substitute

pp-thumbnail